SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-015290
Filing Date
2021-03-15
Accepted
2021-03-15 11:00:27
Documents
92
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT f20f2020_xtlbiopharma.htm 20-F 1574969
2 DESCRIPTION OF SECURITIES REGISTERED f20f2020ex2d_xtlbiopharma.htm EX-2.(D) 93169
3 CERTIFICATION f20f2020ex12-1_xtlbiopharma.htm EX-12.1 11420
4 CERTIFICATION f20f2020ex12-2_xtlbiopharma.htm EX-12.2 11518
5 CERTIFICATION f20f2020ex13-1_xtlbiopharma.htm EX-13.1 5509
6 GRAPHIC image_001.jpg GRAPHIC 5293
7 GRAPHIC image_002.jpg GRAPHIC 77205
  Complete submission text file 0001213900-21-015290.txt   5196815

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE FILE xtlb-20201231.xml EX-101.INS 745887
9 XBRL SCHEMA FILE xtlb-20201231.xsd EX-101.SCH 97312
10 XBRL CALCULATION FILE xtlb-20201231_cal.xml EX-101.CAL 34009
11 XBRL DEFINITION FILE xtlb-20201231_def.xml EX-101.DEF 221543
12 XBRL LABEL FILE xtlb-20201231_lab.xml EX-101.LAB 460328
13 XBRL PRESENTATION FILE xtlb-20201231_pre.xml EX-101.PRE 235091
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 20-F | Act: 34 | File No.: 001-36000 | Film No.: 21740525
SIC: 2834 Pharmaceutical Preparations